Lidegaard O
Department of Obstetrics and Gynaecology, Hvidovre Hospital, University of Copenhagen, Denmark.
BMJ. 1993 Apr 10;306(6883):956-63. doi: 10.1136/bmj.306.6883.956.
To assess the risk of cerebral thromboembolism in women using low dose oral contraceptives.
A retrospective case-control study.
All Danish medical, neurological, neurosurgical, and gynaecological departments.
All 794 women in Denmark aged 15-44 who had suffered a cerebral thromboembolic attack during 1985-9 and 1588 age matched randomly selected controls.
Of 692/1584 case/control questionnaires sent out, 590/1396 (85.3%/88.1%) were returned. Among the cases, 15 refused to participate, 69 had a revised or unreliable diagnosis, 40 had had thromboembolic disease previously, 13 were pregnant, and 152 had a disease predisposing to a cerebral thromboembolic attack. Of the 323 cases without a known predisposition, 320 reported use or non-use of oral contraception. Among the 1396 controls, eight refused to participate, were mentally retarded, or lived abroad; 18 returned an uncompleted questionnaire; 17 had had thromboembolic disease previously; 31 were pregnant; and 130 had a disease predisposing to a cerebral thromboembolic attack. Thus 1198 non-predisposed controls were available, among whom 1197 reported use or non-use of oral contraception. Among the 320 cases, 116 (36.3%) were oral contraceptive users at the time of the cerebral thromboembolic attack. By comparison there were 191 users (16.0%) among the 1197 controls, giving a crude odds ratio of 3.0. After multivariate analysis, including confounder control for age, smoking, years of schooling, and trend in use of different types of oral contraceptives during 1985-90, pills containing 50 micrograms oestrogen were associated with an odds ratio for cerebral thromboembolic attack of 2.9 (95% confidence interval 1.6 to 5.4), those containing 30-40 micrograms oestrogen an odds ratio of 1.8 (1.1 to 2.9), those containing progestogen only an odds ratio of 0.9 (0.4 to 2.4). The odds ratio did not change with increasing age or with duration of oral contraceptive use. A 50% increased risk of a cerebral thromboembolic attacks among cigarette smokers (after confounder control) was independent of oral contraception status and age.
Low dose oral contraceptives are associated with an increased risk of cerebral thromboembolic attack. Combined or sequential pills containing 30-40 micrograms oestrogen are associated with a one third reduced risk compared with preparations containing 50 micrograms oestrogen. Progestogen only pills did not increase the risk of a cerebral thromboembolic attack.
评估使用低剂量口服避孕药的女性发生脑栓塞的风险。
一项回顾性病例对照研究。
丹麦所有的医学、神经科、神经外科和妇科科室。
1985年至1989年间在丹麦发生脑栓塞发作的所有794名15至44岁女性,以及1588名年龄匹配的随机选择的对照者。
在发出的692/1584份病例/对照调查问卷中,590/1396份(85.3%/88.1%)被收回。在病例组中,15人拒绝参与,69人诊断经过修订或不可靠,40人既往有血栓栓塞性疾病,13人怀孕,152人有一种易引发脑栓塞发作的疾病。在323例无已知易患因素的病例中,320例报告了口服避孕药的使用情况或未使用情况。在1396名对照者中,8人拒绝参与、患有智力障碍或居住在国外;18人返回了未完成的问卷;17人既往有血栓栓塞性疾病;31人怀孕;130人有一种易引发脑栓塞发作的疾病。因此,有1198名无易患因素的对照者,其中1197人报告了口服避孕药的使用情况或未使用情况。在320例病例中,116例(36.3%)在发生脑栓塞发作时是口服避孕药使用者。相比之下,在1197名对照者中有191名使用者(16.0%),粗比值比为3.0。经过多变量分析后,包括对年龄、吸烟、受教育年限以及1985年至1990年间不同类型口服避孕药使用趋势的混杂因素控制,含50微克雌激素的药丸与脑栓塞发作的比值比为2.9(95%置信区间为1.6至5.4),含30 - 40微克雌激素的药丸比值比为1.8(1.1至2.9),仅含孕激素的药丸比值比为0.9(0.4至2.4)。比值比不随年龄增长或口服避孕药使用时间而变化。吸烟者发生脑栓塞发作的风险增加50%(在控制混杂因素后),这与口服避孕药使用状况和年龄无关。
低剂量口服避孕药与脑栓塞发作风险增加有关。与含50微克雌激素的制剂相比,含30 - 40微克雌激素的复方或序贯药丸使风险降低三分之一。仅含孕激素的药丸不会增加脑栓塞发作风险。